Previous close | 0.0098 |
Open | 0.0097 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.0097 - 0.0107 |
52-week range | 0.0090 - 0.0820 |
Volume | |
Avg. volume | 6,235,980 |
Market cap | 9.332M |
Beta (5Y monthly) | 1.67 |
PE ratio (TTM) | 1.01 |
EPS (TTM) | 0.0100 |
Earnings date | 25 June 2024 - 29 June 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Natural Shrimp, Inc. (OTCQB: SHMP) (the "Company" or "NSI"), a Biotechnology Aquaculture Company that has developed and patented the first seafood-focused commercially operational RAS (Recirculating Aquaculture System), today announced it has completed at the end of February 2024 a successful 6-month trial in Japan with the Company's patented Electrocoagulation (EC) and Hydrogas™ technologies (the "Equipment").
Natural Shrimp Incorporated (OTCQB: SHMP), a Biotechnology Aquaculture Company (the "Company") that has developed and patented the first seafood-focused commercially operational RAS (Recirculating Aquaculture System), is pleased to announce that the Company has filed an initial application to list its securities on the Chicago Board of Options Exchange (Cboe US) BZX exchange (the "Exchange"). In addition, the Company has extended its engagement with its investment banking partner to underwrite a
NaturalShrimp Incorporated (OTCQB: SHMP), a Biotechnology Aquaculture Company that has developed and patented the first shrimp-focused commercially operational RAS (Recirculating Aquaculture System), is pleased to announce the successful filing of patents in Japan, Thailand, and Australia. These filings mark a significant step in our commitment to advancing sustainable aquaculture practices and ensuring the future of global seafood production.